US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after ...

National Nutrition and Health Survey revealed a startling statistic: nearly 80 percent of Filipino women and 60 percent of ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market ...

Despite an increased risk for complications and death in men after fractures, the US Preventive Services Task Force maintains ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Q3 2025 Earnings Call Transcript January 23, 2025 Operator: Ladies and gentlemen, good day and welcome to the Quarter Three ...